RecoverySoft TissueWound RepairInflammationSoft-tissue, tendon, ligament, and muscle recovery

RESEARCH REFERENCE

TB-500

Synthetic fragment of Thymosin Beta-4 that promotes cell migration and systemic tissue repair.

Quick Reference

Dose: 2–2.5 mg (loading), 2 mg (maintenance)
Frequency / schedule: Loading then maintenance
Route: Subcutaneous
Timing: Flexible
Fasting: Not required
Cycle: 8–12 weeks total (4–6 weeks loading + maintenance)
Time off: 4 weeks off
Common vial strengths: 5 mg, 10 mg

How this works

TB-500 binds G-actin, regulating actin polymerization. This accelerates migration of stem cells, endothelial cells, and keratinocytes to injury sites. It also supports angiogenesis and modulates inflammation. Unlike BPC-157, its action is systemic — injection site does not need to be near the injury.

Benefits + side effects

Potential Benefits

Enhanced cell migration and structural repair
Useful for multiple concurrent injury sites

Side Effects

Injection-site reactions
Transient fatigue or mild flu-like feeling (especially early in loading)
Headache (occasional)

Dosing / Protocol

Reference Protocol

Phase / week	Dose	Frequency	Timing	Notes
Loading (1–6 wks)	2–2.5 mg	2× weekly	Flexible	Build tissue levels
Maintenance	2 mg	1× weekly	Flexible	Sustain

Timing + Fasting Notes

Flexible. Many inject on non-consecutive days (e.g., Mon/Thu). Food does not matter.

Reconstitution

Common vial strengths5 mg, 10 mg

Approved preparation example
Calculate to desired concentration (e.g., 5 mg + 2 mL = 2.5 mg/mL)

Practical Reference

Storage: Lyophilized frozen/refrigerated; reconstituted refrigerated, use within 28 days
Route / injection context: Subcutaneous
Bloodwork / markers: Functional recovery markers, CRP if relevant
Common vial strengths: 5 mg, 10 mg
Cycle / time off: 8–12 weeks total (4–6 weeks loading + maintenance) · 4 weeks off
Practical notes: Systemic — inject anywhere convenient. Research use only.

References

Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500Drug Testing and Analysis · 2012

PRECLINICAL

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.

Search Femetric